The study found that AR-FL and AR-V7 may serve as prognostic biomarkers for high tumor burden in mCRPC patients prior to treatment with Pluvicto, but none of these parameters correlated with response to PSMA treatment. This evidence concerns the gene FOLH1 and neoplasm.